Veradermics’ VDPHL01 Phase 2 Trial Met Key Endpoints In Female Pattern Hair Loss, Showing Rapid Onset Of Hair Growth, 88.9%–90.0% Patient‑Reported Improvement At Month 6; Topline Phase 2/3 Study 306 Results Expected In H1 2027

Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate

Veradermics (NYSE:MANE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 10.77 percent. This is a 97.6 percent increase over losses of $(24.19) per share from the

8-K filing — Veradermics, Inc (MANE)

Filed: 2026-08-11 AccNo: 0001827635-26-000028 Size: 641 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Veradermics shares are trading higher after the company announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss.

Veradermics Presents Data From Phase 2/3 Trial 302 Of VDPHL01 In Male Participants With Mid-To-Moderate Pattern Hair Loss

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the